Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.89
SNPHY's Cash to Debt is ranked higher than
77% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. SNPHY: 2.89 )
SNPHY' s 10-Year Cash to Debt Range
Min: 2.89   Max: No Debt
Current: 2.89

Equity to Asset 0.71
SNPHY's Equity to Asset is ranked higher than
80% of the 754 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. SNPHY: 0.71 )
SNPHY' s 10-Year Equity to Asset Range
Min: 0.71   Max: 0.87
Current: 0.71

0.71
0.87
F-Score: 6
Z-Score: 5.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.88
SNPHY's Operating margin (%) is ranked higher than
87% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.92 vs. SNPHY: 16.88 )
SNPHY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 27.74
Current: 16.88

15.25
27.74
Net-margin (%) 10.32
SNPHY's Net-margin (%) is ranked higher than
81% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. SNPHY: 10.32 )
SNPHY' s 10-Year Net-margin (%) Range
Min: 9.96   Max: 19.25
Current: 10.32

9.96
19.25
ROE (%) 8.68
SNPHY's ROE (%) is ranked higher than
78% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.33 vs. SNPHY: 8.68 )
SNPHY' s 10-Year ROE (%) Range
Min: 8.02   Max: 14.51
Current: 8.68

8.02
14.51
ROA (%) 6.81
SNPHY's ROA (%) is ranked higher than
83% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. SNPHY: 6.81 )
SNPHY' s 10-Year ROA (%) Range
Min: 6.58   Max: 12.13
Current: 6.81

6.58
12.13
ROC (Joel Greenblatt) (%) 33.63
SNPHY's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.20 vs. SNPHY: 33.63 )
SNPHY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 37.82   Max: 53.64
Current: 33.63

37.82
53.64
Revenue Growth (%) 10.80
SNPHY's Revenue Growth (%) is ranked higher than
77% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. SNPHY: 10.80 )
SNPHY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 10.8
Current: 10.8

0
10.8
EBITDA Growth (%) -2.40
SNPHY's EBITDA Growth (%) is ranked higher than
65% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. SNPHY: -2.40 )
SNPHY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 14.3
Current: -2.4

0
14.3
EPS Growth (%) -100.00
SNPHY's EPS Growth (%) is ranked lower than
52% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. SNPHY: -100.00 )
SNPHY' s 10-Year EPS Growth (%) Range
Min: 0   Max: 18.3
Current: -100

0
18.3
» SNPHY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SNPHY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.90
SNPHY's P/E(ttm) is ranked higher than
87% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.30 vs. SNPHY: 22.90 )
SNPHY' s 10-Year P/E(ttm) Range
Min: 11.07   Max: 58.64
Current: 22.9

11.07
58.64
P/B 2.00
SNPHY's P/B is ranked higher than
82% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. SNPHY: 2.00 )
SNPHY' s 10-Year P/B Range
Min: 1.51   Max: 2.38
Current: 2

1.51
2.38
P/S 2.50
SNPHY's P/S is ranked higher than
79% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. SNPHY: 2.50 )
SNPHY' s 10-Year P/S Range
Min: 2.14   Max: 10.23
Current: 2.5

2.14
10.23
PFCF 19.30
SNPHY's PFCF is ranked higher than
94% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SNPHY: 19.30 )
SNPHY' s 10-Year PFCF Range
Min: 11.35   Max: 41.93
Current: 19.3

11.35
41.93
EV-to-EBIT 11.93
SNPHY's EV-to-EBIT is ranked higher than
92% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.17 vs. SNPHY: 11.93 )
SNPHY' s 10-Year EV-to-EBIT Range
Min: 5.2   Max: 13.5
Current: 11.93

5.2
13.5
Current Ratio 2.80
SNPHY's Current Ratio is ranked higher than
77% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. SNPHY: 2.80 )
SNPHY' s 10-Year Current Ratio Range
Min: 2.8   Max: 7.34
Current: 2.8

2.8
7.34
Quick Ratio 2.43
SNPHY's Quick Ratio is ranked higher than
78% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. SNPHY: 2.43 )
SNPHY' s 10-Year Quick Ratio Range
Min: 2.43   Max: 6.38
Current: 2.43

2.43
6.38

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.10
SNPHY's Dividend Yield is ranked higher than
57% of the 489 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. SNPHY: 1.10 )
SNPHY' s 10-Year Dividend Yield Range
Min: 1.16   Max: 3.2
Current: 1.1

1.16
3.2
Dividend growth (3y) -100.00
SNPHY's Dividend growth (3y) is ranked higher than
63% of the 359 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. SNPHY: -100.00 )
SNPHY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -100
Current: -100

Yield on cost (5-Year) 1.10
SNPHY's Yield on cost (5-Year) is ranked higher than
67% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. SNPHY: 1.10 )
SNPHY' s 10-Year Yield on cost (5-Year) Range
Min: 1.16   Max: 3.2
Current: 1.1

1.16
3.2
Share Buyback Rate 100.00
SNPHY's Share Buyback Rate is ranked higher than
99% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.20 vs. SNPHY: 100.00 )
SNPHY' s 10-Year Share Buyback Rate Range
Min: 0   Max: -0.8
Current: 100

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.30
SNPHY's Price/Net Cash is ranked higher than
80% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SNPHY: 18.30 )
SNPHY' s 10-Year Price/Net Cash Range
Min: 4.94   Max: 16.14
Current: 18.3

4.94
16.14
Price/Net Current Asset Value 12.40
SNPHY's Price/Net Current Asset Value is ranked higher than
68% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SNPHY: 12.40 )
SNPHY' s 10-Year Price/Net Current Asset Value Range
Min: 4.35   Max: 11
Current: 12.4

4.35
11
Price/Tangible Book 2.80
SNPHY's Price/Tangible Book is ranked lower than
52% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. SNPHY: 2.80 )
SNPHY' s 10-Year Price/Tangible Book Range
Min: 1.68   Max: 2.43
Current: 2.8

1.68
2.43
Price/DCF (Projected) 1.40
SNPHY's Price/DCF (Projected) is ranked higher than
60% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.11 vs. SNPHY: 1.40 )
SNPHY' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 1.4

Price/Median PS Value 1.20
SNPHY's Price/Median PS Value is ranked lower than
52% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. SNPHY: 1.20 )
SNPHY' s 10-Year Price/Median PS Value Range
Min: 0.92   Max: 3.99
Current: 1.2

0.92
3.99
Price/Graham Number 2.00
SNPHY's Price/Graham Number is ranked higher than
56% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.82 vs. SNPHY: 2.00 )
SNPHY' s 10-Year Price/Graham Number Range
Min: 1   Max: 1.55
Current: 2

1
1.55
Earnings Yield (Greenblatt) 8.40
SNPHY's Earnings Yield (Greenblatt) is ranked higher than
88% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. SNPHY: 8.40 )
SNPHY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7.4   Max: 19.3
Current: 8.4

7.4
19.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:4536.Japan, SZD.Germany, 4536.Japan
SANTEN PHARMACEUTICAL CO., LTD. produces and sells ophthalmic medicine. It manufactures a variety of products including eye drops and ointments. It also imports lenses and tools and equipment used by optometrists and produces anti-rheumatic drugs.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK